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ABSTRACT  
The human kallikrein-related peptidases (KLK) are serine proteases whose concentrations are 
often abnormal in common human malignancies and contribute to neoplastic progression 
through multifaceted roles. However, little attention has been paid to their synthesis and 
involvement in the development and dissemination of lung cancer, the leading cause of cancer 
mortality worldwide.  
We have analyzed the production of KLK6 in normal lung and tumor tissues from patients 
with Non-Small Cell Lung Cancer (NSCLC). KLK6 immunoreactivity was restricted to 
epithelial cells of the normal bronchi, but most of the cancer samples were moderately or 
highly immunoreactive, regardless of the histological subtype. In contrast, little or no KLK6 
was detected in NSCLC cells. We have developed NSCLC lines expressing wild type KLK6 
in order to investigate the role of KLK6 in lung cancer biology, and analyzed its impact on 
proliferation. Ectopic KLK6 dramatically enhanced NSCLC cell growth and KLK6-producing 
NSCLC cells had accelerated cell cycles, between the G1 and S phases. This was 
accompanied by a marked increase in cyclin E and decrease in p21. KLK6 production was 
also associated with enhanced synthesis of c-Myc, which is known to promote cell-cycle 
progression. Finally, examination of specimens from patients with NSCLC revealed that 
KLK6 mRNA is overexpressed in tumor tissue, and high KLK6 concentrations were 
associated with lower survival rates. We conclude that a high concentration of KLK6 is an 
indicator of tumor proliferation and an independent predictive factor in NSCLC.   
 
 
KEY WORDS: NSCLC, kallikrein related peptidase, KLK6, overexpression, cell 
proliferation, cell cycle, c-Myc, cyclin, survival 
Page 2 of 24Journal of Cellular and Molecular Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 3 
INTRODUCTION 
Human kallikrein-related peptidase 6 (KLK6) belongs to a family of secreted serine proteases 
encoded by 15 homologous genes (KLK1-KLK15) that are important factors in cancer 
proteolysis. KLK production is abnormal, due to disturbed gene transcription or protein 
synthesis, or both, in many common human malignancies, highlighting the clinical relevance 
of KLKs as markers for tumor diagnosis and follow-up [1].  
KLK6 is present in a myriad of normal tissues including the brain, breast, salivary gland, 
colon, pancreas, skin, lung and biological fluids [3-6]. Several studies have found that KLK6 
synthesis is abnormal in endocrine-related tumors such as ovarian and uterine carcinomas, and 
non-cancer diseases, suggesting its utility as a marker [1, 7-10]. The concentration of KLK6 is 
also increased in human skin diseases and this concentration is correlated with tumor 
progression [11]. The clinical use of KLK6 for diagnosing gastric and colon cancer has been 
discussed recently [11, 12]. While the biological role of KLK6 in these tissues has not yet 
been identified, several studies have shown how KLK6 contributes to various phases of 
cancer biology. KLK6 might promote tumor invasion by breaking down extracellular matrix 
components and stimulating cell proliferation [11, 13, 14]. However, the molecular 
mechanism by which it stimulates proliferation remains unclear. Despite these findings, little 
work has been done on KLK6 synthesis and function in lung cancer, the most common and 
the largest single cause of death from cancer worldwide [6].  
 
We have analyzed the concentration and distribution of KLK6 in normal lung tissue and in 46 
tissue samples from patients with a primary non-small cell lung cancer (NSCLC). KLK6 was 
abundant in both adenocarcinoma and squamous cell carcinoma NSCLC subtypes, but there 
was little or no KLK6 in a panel of NSCLC lines. We therefore investigated the role of KLK6 
in lung cancer biology by transfecting NSCLC cells with the native form of KLK6. Ectopic 
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KLK6 production increased NSCLC cell proliferation, due to the acceleration of cell cycle 
progression through the G1-S transition via the induction of cyclin E and repression of p21. 
KLK6 synthesis was also associated with increased c-Myc production, a key player in cell-
cycle progression. Lastly, a quantitative study of matched tumor and non-tumor specimens 
from NSCLC patients revealed an overabundance of KLK6 transcripts that was correlated 
with an unfavorable patient outcome. Our findings indicate that KLK6 is involved in lung 
cancer proliferation and is an indicator of a poor prognosis. 
 
 
MATERIAL AND METHODS 
Antibodies. Polyclonal antibodies against KLK6, cyclin E and p21 were obtained from Santa 
Cruz Biotechnology, Inc. Monoclonal antibody against KLK6 was purchased from Serotec 
Immunological Excellence. Other antibodies were from Cell Signaling Technology Inc. 
 
Tissue samples and microarray. Matched tumor and non-tumor tissue samples from forty-
six patients with primary NSCLC (histological diagnosis and clinical history reported in 15 
and 16] were used in this study. All investigations were carried out according to Helsinki 
principles and French bioethical regulations. Non-necrotic tumor samples, identified by a 
pathologist from formalin fixed and paraffin embedded tumor blocks, were used to prepare 
tissue microarrays. Frozen tumor samples from the same cohort of patients and matched 
tumor and non-tumor tissues from eleven additional patients were used to analyze transcript 
production. 
 
Immunohistochemistry. Immunohistochemical analysis of KLK6 used a monoclonal 
antibody and the DakoCytomation EnVision system suitable for rabbit or mouse primary 
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antibodies, according to the manufacturer’s instructions. Staining was revealed with 3,3-
diaminobenzidine (Dako Cytomation). Staining intensity and the percentage of stained cells 
were graded semi-quantitatively by a pathologist using standard procedures.  
 
Cell lines and culture conditions. The following human NSCLC cell lines were obtained 
from the American Type Culture Collection (ATCC, LGC Promochem, France): 
bronchioloalveolar carcinoma cell line A549, squamous cell carcinoma cells H520, Calu-1, 
adenocarcinoma cell lines H23, H1838 and H522, and large cell carcinoma line H460. All the 
cells were grown in the recommended culture medium. The A549 Flp-In cell line was derived 
from A549 cells genetically modified in our laboratory. A549 Flp-In cells contain a unique 
recombinase-mediated DNA integration site (FLP Recombination Target (FRT)) at a 
transcriptionally active genomic locus and are resistant to zeocin (data not shown). A3-KLK6 
and A5-KLK6 are stable clones derived from A549 Flp-In, that express the native form of 
KLK6 and are resistant to hygromycin. A549 Flp-In parental or KLK6-expressing cells were 
grown at 37 °C in an atmosphere of 5% CO2 in RPMI-1640 Glutamax I, except Calu-1 that 
was cultured in McCoy’s 5a medium, containing 10% fetal bovine serum (FBS), 100U/mL 
penicillin, 100µg/mL streptomycin and if necessary supplemented with either 100µg/mL 
zeocin or 100µg/mL hygromycin.  
 
Plasmids and stable transfections. The complete coding sequence of KLK6 (144-1002 bp 
from NM_002774) with Stop codon was amplified by PCR and integrated into the T/A 
cloning site of pcDNA5/FRT/V5-His TOPO (Invitrogen Corp.), which contains an FRT site. 
The sequences of the specific primers are available on request. The expression vector and the 
plasmid encoding the yeast Flp recombinase were co-transfected into A549 Flp-In using 
Lipofectamine 2000 (Invitrogen Corp.) according to the manufacturer’s instructions. Stable 
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clones containing the gene of interest iserted into the genome at the FRT site were selected 
and amplified. KLK6 secretion into the supernatants of clones was analyzed by Western 
blotting.  
 
Cell proliferation assays. Cells were seeded (2.5x10
3
 cells/well) in 96-well plates and 
allowed to grow for 24-96 hours. Cells were harvested at appropriate times and counted using 
a Malassez hematimeter.  
 
Cell cycle synchronization. Cells were seeded (4x10
5
 cells/well) in 6-well plated and grown 
for 24 hours. They were then synchronized by starving them of serum in RPMI-1640 for 24 
hours to arrest the cell cycle in G0-G1 [17].  The medium was then changed to RPMI-1640 
containing 5% FCS and 3 mM hydroxyurea for another 24 hours so that the cells accumulated 
at the end of G1. These cells were extensively washed and placed in fresh medium containing 
5% FCS to continue dividing. Cells were harvested at various times after being released, fixed 
in cold methanol and stored at -20°C. Cell samples taken at the indicated times were also 
processed for cyclin and other cell cycle regulator analysis by Western blotting.  
 
Cell cycle analysis. The methanol was removed from stored cells and they were treated with 
the Coulter DNA-Prep reagents kit (Beckman Coulter). Cell cycle distribution was analyzed 
with the Multicycle-AV software (Phoenix Flow Systems) [17].  
 
Protein extraction and Western blotting. Cells were seeded in 6-well plates (5.10
5
 
cells/well) or in 75cm
2 
flasks and grown in appropriate maintenance cell culture medium for 
24 hours. They were then harvested and proteins were extracted. The proteins were loaded on  
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gels for SDS-PAGE and then electro-transferred to PVDF membranes [18]. Immunodetection 
was performed according to the antibody manufacturer’s instructions. 
 
RNA extraction, RT-PCR and quantitative real-time RT-PCR. Total RNA was extracted 
from NSCLC cells using the RNeasy Minikit from Qiagen Inc. according to the 
manufacturer’s instructions. Total RNA (2 µg) was reverse transcribed using 200 units of 
SuperScript III RNase H Reverse Transcriptase (Invitrogen Corp.) following the 
manufacturer’s instructions. 1/10 of the cDNA was amplified by PCR using FastStart Taq 
DNA Polymerase (Roche Diagnostics) according to the manufacturer’s instructions. 
Reactions were performed under the following conditions for both KLK6 and ß-actin: an 
initial denaturation step at 95°C for 3 min, followed by 35 cycles of denaturation at 95°C for 
30 s, annealing at 55.8°C for 30 s, and extension at 72°C for 30 s. The following primers were 
used: KLK6 For 5'-AAG ACA GCA GAT GGT GAT-3'; KLK6 Rev 5'-CTG GCT TCT CCT 
TTG AT-3' located on different exons; ß-actin For 5'-GGC GGC ACC ACC ATG TAC CCT-
3'; and ß-actin Rev 5'-AGG GGC CGG ACT CGT CAT ACT-3'. 
Total RNA from tissues was extracted and reverse-transcribed, and KLK6 transcripts 
quantified by real-time PCR as previously described [15, 16]. The primer sets were designed 
to target two exons (KLK6 For 5’- tga tgg tgg tgc tga gt-3’; KLK6 Rev 5’-aca gtg gat gga taa 
gga c-3’). The cycling conditions were 95 °C for 5 min, followed by 50 cycles of 95 °C for 
10 s, 65 °C for 15 s, and 72 °C for 20 s. Fluorescent product was measured by a single 
acquisition mode for 15 s after each cycle. Gene expression was normalized to the amount of 
18S rRNA. 
 
Statistical analysis. The differences in the KLK6 in non-cancerous and tumor tissues were 
analyzed with the non-parametric Wilcoxon test for matched samples. The results of 
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proliferation and synchronization assays are expressed as medians and clones and parental 
cells are compared using the Kruskal-Wallis non-parametric test. The survival curves for 
high-KLK6 and low-KLK6 cells were compared using a log-rank test. Cox proportional 
hazards models [19] were also used to assess the difference in the overall survival probability 
between groups with high-KLK6 and low-KLK6 after adjustment for clinical-pathological 
variables. These variables included gender, age, histological type, tumor size, nodal tumor 
status, stage and smoking status (packs/year). We used the Wald test to determine the 
statistical significance of the survival difference. A P-value below or equal to 0.05 was 
considered statistically significant.  
 
 
RESULTS 
 
KLK6 is present in both normal lungs and NSCLC tissues but not in NSCLC cell lines.  
We determined the KLK6 in normal lung tissues and in 46 tumor specimens from patients 
with primary NSCLC. There was moderate KLK6 immunoreactivity in the epithelium of the 
bronchial tree of normal lungs with the signal concentrated at the apical pole of cells, but type 
I and II pneumocytes were negative (figure 1A).  There was diffuse cytoplasmic staining for 
KLK6 in most of the tumor cells of NSCLC. Semi-quantitative assessment of 
immunoperoxidase labeled KLK6 in a tissue micro-array containing 46 tumor samples from 
NSCLC patients showed two populations: 25% of cases were low-KLK6 and 75% of the 
cases were high-KLK6. Statistical analysis of KLK6 staining scores and clinical-pathological 
parameters revealed that KLK6 synthesis was not correlated with either the histological type, 
the tumor size, the nodal/tumor status, or tumor stage.  
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However analysis of the KLK6 mRNA in a panel of NSCLC cell lines by RT-PCR revealed 
few or no KLK6 transcripts (figure 1B). Similarly, KLK6 protein was not detected in either 
the cell lysate or the culture supernatants of those lines that were slightly positive by RT-PCR 
(data not shown). Thus, in contrast to tissue specimens, KLK6 was not produced in the cell 
lines derived from NSCLC.  
 
Ectopic KLK6 increases the proliferation of NSCLC cells. As there was little or no KLK6 
in the NSCLC cells we tested, we produced NSCLC lines synthesizing pre-proKLK6 in order 
to investigate further the role of KLK6 in lung cancer biology. The cDNA encoding pre-
proKLK6 was inserted into the A549 Flp-In by homolog recombination to give stable 
isogenic clones [20]. Two clones that produced KLK6 and the control parental A549 Flp-In 
line were selected for further study (figure 2A). Because previous reports suggest that KLK6 
production influences cell proliferation [11, 12], we assessed the growth of both parental and 
KLK6-producing A549 cells grown at low density for 96 hours.  The two clones producing 
KLK6 grew significantly faster than the A549 Flp-In cells after 72 hours in culture (Figure 
2B). The growth of a non-pulmonary line (HEK-293 Flp-In) genetically modified to produce 
KLK6 was similarly enhanced, but that of the same cells producing another KLK was not 
(data not shown).  
 
Ectopic KLK6 accelerates cell cycle progression in NSCLC lines.  We synchronized cells 
at the end of G1 phase and then released them in the cell cycle to analyze their progression. 
Starvation and hydroxyurea treatment resulted in the arrest of nearly 85% of the cells in G1 
phase (figure 3A). The cell cycle distribution of cells producing KLK6 5 and 8 hours after 
release from hydroxyurea was quite different from that of the control line. Significantly more 
KLK6-producing A549 cells accumulated in the S and G2 phases (Figure 3B), suggesting that 
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the KLK6-producing NSCLC cells passed more rapid through the S and next G2 phases. 
Analysis of the cyclins regulating the G1 to S transition by Western blotting revealed that 
there was considerably more cyclin E in KLK6-producing cells than in the parental line 5 
hours after release of the cell cycle, while the amounts of cyclins D1 and D3 remained the 
same in all the cell lines (Figure 3C). There was also a dramatic decrease in the amount of 
p21, an inhibitor of cyclin-dependent kinases that limit cell cycle progression, in the KLK6-
producing cells both 5 and 8 hours after release from hydroxyurea.  
 
KLK6-dependent enhancement of cell cycle progression might be mediated by c-Myc. 
The dramatic changes in the replication rate and cell cycle progression associated with ectopic 
KLK6 production indicated that the cell proliferation regulators in KLK6-producing A549 
cells were severely disrupted. Therefore, we analyzed the expression of c-Myc, a proto-
oncogene that is often constitutively overexpressed in lung cancers and promotes cell cycle 
progression by inducing the genes encoding cyclins D2, -E and –A and repressing cell growth 
arrest genes like p21 [21-23]. KLK6-producing cells had markedly more c-Myc protein than 
control cells, both when they were grown in complete medium (data not shown) and when 
released from hydroxyurea in the cell cycle (figure 3C).   
 
High KLK6 expression by NSCLC is associated with poor patient survival. 
Because our findings suggest that KLK6 overproduction plays a dramatic role in lung cancer 
development by promoting NSCLC cell proliferation, we compared KLK6 gene expression in 
samples of tumor and non-tumor tissues from 57 patients with primary NSCLC.  There was 
significantly more KLK6 mRNA (median value 23-fold more) in cancer tissue than in normal 
lung tissue (Figure 4A). We analyzed the relationship between the amount of KLK6 
transcripts and clinicalpathological parameters by univariate analysis. A high KLK6 
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expression was not correlated with any clinicopathological lung tumor variable (data not 
shown). 
We then studied the association between the KLK6 status and overall patient survival using 
both Kaplan-Meier survival curves and the Cox proportional hazards regression model. There 
was a significant correlation between NSCLC cells with a high concentration of KLK6 
transcripts and poor patient survival (figure 4B and C).  The hazard ratio measuring the effect 
of KLK6 on the overall survival estimated from the Cox model was 5.79, which is highly 
significant (p=0.001; 95% CI, 2.147-15.622). The overall survival at 40 months of patients 
whose NSCLC cells were low-KLK6 was about 95%, while it was about 60% in the patients 
with a high-KLK6 NSCLC. Because the Cox regression model was adjusted for the clinical-
pathological variables, the effect of KLK6 was significantly associated with the overall 
survival independently of the other risk factors.  
 
 
 
DISCUSSION 
 
The human kallikrein-related peptidases, KLKs, have emerged as multifaceted players in 
cancer proteolysis over the past decade. Numerous studies have shown that KLK synthesis 
and proteolytic activity is altered in common types of human malignancies [1]. Although most 
of the studies focused on hormone-dependent tumors, there is recent evidence that KLK 
production is abnormal in other types of human malignancies [1, 11, 12]. We first 
demonstrated that several KLKs are produced in the lung and that the synthesis of some of 
them is deregulated in NSCLC [15, 16, 24]. However, little is known on the involvement of 
the KLK-related peptidases in this disease. Sher et al. reported that KLK8 suppresses tumor 
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growth and invasion in vitro and in vivo, and confers a favorable clinical outcome for patients 
with lung cancer [25]. Herein, we examined the KLK6 status and implication in NSCLC. Our 
immunohistochemical study on a sizeable cohort of patients with lung cancers shows that 
KLK6 is often present in NSCLC, and that its concentration may be moderate or high. In 
contrast to Singh et al [6], we detected KLK6 in both adenocarcinoma and squamous cell 
carcinomas, the major histological subtypes of NSCLC. This discrepancy might be attributed 
to the different anti-KLK6 antibodies used for IHC, or a rare phenotype encountered in the 
single adenocarcinoma sample examined by these authors.  
Strikingly, we did not detect KLK6 in a panel of NSCLC cell lines, suggesting that there is 
little or no KLK6 in the lines derived from NSCLC tumors. Deregulation of KLK6 in NSCLC 
cell lines might be attributed to multiple mechanisms including genetic alterations 
(polymorphisms), hypermethylation in permanent cancer cell lines compared to their primary 
counterpart due to the culture conditions, or lack of regulatory factors in the growing medium 
as previously described [1, 26, 27]. Recently, hypermethylation of the KLK6 promoter 
leading to KLK6 gene silencing has been described in metastatic breast cancer cell lines 
[28].Moreover, accumulating evidences highlighted the importance of the interactions 
between cancer cells and the dynamic microenvironment in which they live (containing 
soluble and non soluble components of the extracellular matrix and “activated” non neoplastic 
cells) in the regulation of gene expression in cancer cells [26, 29].  Further studies are now 
required to elucidate exactly how KLK6 gene expression is controlled in NSCLC tissues and 
cell lines.  
 
KLKs have recently been implicated in various phases of cancer. They may act alone or as 
part of a proteolytic cascade in which KLKs collaborate with other KLKs and cancer-
associated proteases, to stimulate or inhibit tumor development and dissemination [1, 7, 14, 
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25, 30]. Recent studies on the overexpression of the mouse orthologue Klk6 gene in 
keratinocytes, and the silencing of KLK6 gene expression in a gastric cancer line, indicate that 
KLK6 is involved in cell proliferation. In the light of these findings and our results showing 
the abundance of KLK6 in NSCLC, we postulate that KLK6 contributes to lung cancer 
development by promoting cell proliferation [11, 12]. This agrees well with our finding that 
ectopic KLK6 dramatically accelerates NSCLC cell growth. The results from our group and 
others indicate that both the human and mouse kallikrein 6 orthologues promote cell growth, 
and this KLK6-mediated proliferation is cell-type independent. 
Because the molecular mechanisms underlying the KLK6-mediated enhancement of cell 
growth is unknown, we investigated the impact of KLK6 synthesis on the progression of 
NSCLC cell cycle. We found that KLK6-producing cells passed through the S and the next 
G2 phases faster than the controls, and that they produced more cyclin E, that regulates the 
G1-S phase transition of the cell-cycle. And the production of ectopic KLK6 by NSCLC was 
accompanied by a significant decrease in p21, an inhibitor of cyclin–dependent kinases. These 
kinases are key regulatory enzymes connected to cyclins. Thus, the promotion of cell growth 
by KLK6 is due to an acceleration of the G1-S transition following the induction of cyclin E 
and repression of p21. We also found that the synthesis of KLK6 is associated with an 
increase in c-Myc synthesis by both synchronized cells and cells cultured in standard 
conditions (data not shown). The c-Myc gene belongs to the MYC family of oncogenes that 
are often overexpressed in lung cancers [21]. One of the key functions of c-Myc is to regulate 
cell-cycle progression by activating cyclin D and E complexes and repressing p21, which 
governs cell cycle/growth arrest [21-23, 31]. Based on our results, we speculated that KLK6-
mediated c-Myc enhancement leads to acceleration of cell cycle progression in lung tumor 
cells. Further experiments are required to validate this hypothesis, and determine the 
molecular mechanism associated with higher c-Myc expression.  
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Lung cancer is the leading cause of cancer mortality worldwide, with over one million deaths 
each year [32]. Most patients are diagnosed with advanced NSCLC, and the overall 5-year 
survival remains dismal (15% all stages included), despite recent advances in multi-modal 
therapy. Although a minority of patients present with stage I disease and undergo surgery 
alone, 35-50% relapse within 5 years. Therefore, early diagnosis and identification of specific 
high-risk patients are crucial for improving the management of patients with NSCLC. 
Because the synthesis of KLKs is often abnormal in common types of human malignancies, 
numerous studies have focused on the clinical value of KLKs for tumor diagnosis and follow-
up [1]. Several KLKs are approved (like KLK3 or PSA) or emerging markers of endocrine 
tumors [1]. Recently, a multiparametric panel of serological KLKs has been proposed for lung 
cancer diagnosis [33]. The present report indicates that the KLK6 gene is markedly 
overexpressed in lung cancer tissue, and that high KLK6 mRNA expression is significantly 
correlated with a poor patient outcome, according to both univariate and multivariate analysis. 
Moreover, the fact that the effect of KLK6 remains significant after adjustment for other 
clinical-pathological variables indicates that it is an independent prognostic factor. Elevated 
KLK6 expression, both at the mRNA and protein levels, has been previously described as 
independent adverse prognostic marker in a subgroup of ovarian carcinomas and in colorectal 
and gastric cancers [8, 12]. 
 
In conclusion, we show that KLK6 is a proliferative factor in NSCLC that might act by 
inducing c-Myc synthesis, which in turn modulates specific components of the cell cycle 
machinery to promote cell cycle progression. Our present results, together with those from 
previous reports showing the influence of KLK6 on cancer cell migration and invasion [11, 
13], suggest that KLK6 plays a central role in NSCLC development and progression. Finally, 
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high concentrations of KLK6 might be an unfavourable prognosis factor because a high 
KLK6 concentration is associated with a poor clinical outcome of patients with NSCLC.  
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FIGURE LEGENDS 
Figure 1. KLK6 in tissues from patients with NSCLC but not in NSCLC-derived cell 
lines. A, Immunohistochemistry of KLK6 in normal and malignant lung from 46 patients with 
primary NSCLC using a monoclonal antibody (original magnification: X200; hematoxylin 
counterstain). KLK6 immunostaining (dark) in the apical region of normal bronchial 
epithelial cells (thin arrow) and in the cytoplasm of most cancer cells (large arrow). B, KLK6 
production in a panel of NSCLC lines by RT-PCR. Total RNA from NSCLC cell lines was 
extracted and reverse-transcribed. KLK6 and β-actin (internal control) mRNAs were 
amplified from cDNA by PCR and the amplification products were separated on a 1% agarose 
gel containing ethidium bromide. 1. A549; 2. Calu-1; 3. H23; 4. H460; 5. H520; 6. H522; 7. 
H1838; +: plasmid containing KLK6 cDNA. 
 
Figure 2. Ectopic KLK6 in NSCLC promotes proliferation. A, Secretion of KLK6 by 
A549 Flp-In and stable isogenic clones (A3- and A5-KLK6) assessed by Western blotting 
using a polyclonal anti-KLK6 antibody. Equal volumes of cell culture supernatant were 
loaded onto 12% SDS-PAGE gels. B, Control A549 Flp-In (dashed line) and A3-KLK6 (black 
full line) and A5-KLK6 (grey full line) (2.5x10
3
 cells of ach) were seeded and cells were 
counted at the indicated times. Points, median value of triplicate determinations from one 
representative experiment (of three). Bars, lower and upper quartiles. P values were 
determined using a Kruskal & Wallis test. * P<0.05. 
 
Figure 3. Effect of KLK6 on NSCLC cell growth and regulation of cell cycle progression. 
A, Distribution of control A549 Flp-In and A3-KLK6 and A5-KLK6 cells within the G1 
(white), S (grey) and G2 (black) phases of the cell cycle 0, 5 or 8 hours after release from 
hydroxyurea.  Results are expressed as the median values of five independent experiments. B, 
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Box plot of control A549 Flp-In and A3-KLK6 and A5-KLK6 cells passed from G1 into 
G2+S phases 5 hours and 8 hours after release from hydroxyurea. Results are representative 
of five independent experiments. P values were determined using a Kruskal & Wallis test. * 
P< 0.05, ** P<0.025. C, Assay of cell-cycle proteins and c-Myc by Western blotting of 
whole-cell extracts (50µg) from the control A549 Flp-In, A3-KLK6 and A5-KLK6 lines 5 and 
8 hours after release from hydroxyurea. Actin protein was used to check for equal loading.  
Results are from one of three experiments. 
 
Figure 4. KLK6 overexpression in tumor tissues from patients with NSCLC, and patient 
survival. A, Box plot of KLK6 transcript concentration by quantitative real-time RT-PCR in 
57 tumors and matched non tumor samples from patients with primary NSCLC undergoing an 
initial surgical resection of the lung tumor (aged 44–83 years, median: 65). Gene expression 
was normalized to the amount of 18S rRNA and is reported in arbitrary units. Median values 
are indicated in italics. The difference between the concentration of KLK6 transcripts in non-
tumor and tumor tissues was determined by a Wilcoxon test for matched pairs. B, Kaplan-
Meier curves for overall survival of patients with high and low concentrations of KLK6 
mRNA in lung tumor tissues. The optimal cut-off value for survival analysis was identified by 
the χ2 test, based on the ability of KLK6 to predict the overall survival of the population 
studied. Using this cutoff, KLK6 mRNA concentration was categorized as high or low. A 
cutoff of 600 (in arbitrary units) for KLK6 mRNA was equal to the 56th percentile. C, 
Survival curves obtained from Cox regression models after adjusting for gender, age, 
histological type, tumor size, nodal tumor status, stage and smoking status (packs/ year). 
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Figure 1. KLK6 in tissues from patients with NSCLC but not in NSCLC-derived cell lines. A, 
Immunohistochemistry of KLK6 in normal and malignant lung from 46 patients with primary NSCLC 
using a monoclonal antibody (original magnification: X200; hematoxylin counterstain). KLK6 
immunostaining (dark) in the apical region of normal bronchial epithelial cells (thin arrow) and in 
the cytoplasm of most cancer cells (large arrow). B, KLK6 production in a panel of NSCLC lines by 
RT-PCR. Total RNA from NSCLC cell lines was extracted and reverse-transcribed. KLK6 and β-actin 
(internal control) mRNAs were amplified from cDNA by PCR and the amplification products were 
separated on a 1% agarose gel containing ethidium bromide. 1. A549; 2. Calu-1; 3. H23; 4. H460; 
5. H520; 6. H522; 7. H1838; +: plasmid containing KLK6 cDNA.  
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Figure 2. Ectopic KLK6 in NSCLC promotes proliferation. A, Secretion of KLK6 by A549 Flp-In and 
stable isogenic clones (A3- and A5-KLK6) assessed by Western blotting using a polyclonal anti-KLK6 
antibody. Equal volumes of cell culture supernatant were loaded onto 12% SDS-PAGE gels. B, 
Control A549 Flp-In (dashed line) and A3-KLK6 (black full line) and A5-KLK6 (grey full line) 
(2.5x103 cells of each) were seeded and cells were counted at the indicated times. Points, median 
value of triplicate determinations from one representative experiment (of three). Bars, lower and 
upper quartiles. P values were determined using a Kruskal & Wallis test. * P<0.05.  
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Figure 3. Effect of KLK6 on NSCLC cell growth and regulation of cell cycle progression. A, 
Distribution of control A549 Flp-In and A3-KLK6 and A5-KLK6 cells within the G1 (white), S (grey) 
and G2 (black) phases of the cell cycle 0, 5 or 8 hours after release from hydroxyurea.  Results are 
expressed as the median values of five independent experiments. B, Box plot of control A549 Flp-In 
and A3-KLK6 and A5-KLK6 cells passed from G1 into G2+S phases 5 hours and 8 hours after 
release from hydroxyurea. Results are representative of five independent experiments. P values 
were determined using a Kruskal & Wallis test. * P< 0.05, ** P<0.025. C, Assay of cell-cycle 
proteins and c-Myc by Western blotting of whole-cell extracts (50µg) from the control A549 Flp-In, 
A3-KLK6 and A5-KLK6 lines 5 and 8 hours after release from hydroxyurea. Actin protein was used 
to check for equal loading.  Results are from one of three experiments.  
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Figure 4. KLK6 overexpression in tumor tissues from patients with NSCLC, and patient survival. A, 
Box plot of KLK6 transcript concentration by quantitative real-time RT-PCR in 57 tumors and 
matched non tumor samples from patients with primary NSCLC undergoing an initial surgical 
resection of the lung tumor (aged 44–83 years, median: 65). Gene expression was normalized to 
the amount of 18S rRNA and is reported in arbitrary units. Median values are indicated in italics. 
The difference between the concentration of KLK6 transcripts in non-tumor and tumor tissues was 
determined by a Wilcoxon test for matched pairs. B, Kaplan-Meier curves for overall survival of 
patients with high and low concentrations of KLK6 mRNA in lung tumor tissues. The optimal cut-off 
value for survival analysis was identified by the χ2 test, based on the ability of KLK6 to predict the 
overall survival of the population studied. Using this cutoff, KLK6 mRNA concentration was 
categorized as high or low. A cutoff of 600 (in arbitrary units) for KLK6 mRNA was equal to the 56th 
percentile. C, Survival curves obtained from Cox regression models after adjusting for gender, age, 
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